title: [Symptomatic treatment and palliative care of ALS].
abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, affecting upper and lower motor neurons, which eventually progresses to respiratory deterioration and death in most of the patients. Only one drug, riluzole, has been approved for the treatment of ALS. The drug has a benefit, prolonging life by 3-6 months, but the disease progresses inexorably, with no better quality of life. The fundamental role of medicine is sometimes to cure, but always to bring comfort. In current situation, ALS patients need adequate palliative care more than anything else. Prognosis and treatment options should be discussed with the patient and the relatives, but full information about the prognosis may deprive the patient of hope. However, disclosure of the prognosis is necessary to obtain informed consent for management decisions such as tracheostomy and artificial ventilation. Nasal positive-pressure ventilation (BiPAP) is an alternative to tracheostomy, at least for some patients without advanced bulbar impairment. Nutritional status in patients who cannot swallow can be efficiently improved by a percutaneous endoscopic gastrostomy. (PEG).
authors.affiliation: Klinika Neurologii, Akademia Medyczna w Warszawie.
authors.forename: H
authors.initials: H
authors.lastname: Kwieciński
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy*; D006801:Humans; D059408:Pain Management; D010166:Palliative Care; D011175:Positive-Pressure Respiration; D011788:Quality of Life